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c Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, USASepsis is a common, costly and lethal condition with high mortality
and substantial long-term disability in survivors.With high rates of sepsis
at the extremes of age (premature infants and the elderly), growth of
both of these populations will lead to an increase in sepsis burden in
years to come. Development of targeted sepsis therapies, of which there
are currently none, is a priority. In recent years, our group and others
have described high levels of circulating cell-free hemoglobin (Hb) in
the majority of patient with sepsis (Janz et al., 2013; Adamzik et al.,
2012) and have shown that higher levels are associatedwith poor clinical
outcomes. Pre-clinical studies have begun to dissect themolecular mech-
anisms of the damaging effects of cell-free Hb in sepsis, most of which
have focused on the endothelium (Lisk et al., 2013) or macrophages
(Lin et al., 2010) and not on neutrophils. In this issue of the journal, the
study by Lee et al. (2015) brings us one step closer to understanding the
pathophysiologic role of circulating cell-free Hb in sepsis. The authors
show that oxidized Hb, speciﬁcally methemoglobin (metHb), is a
damage-associated molecular pattern (DAMP) that signals through the
Toll-like receptor (TLR) 2/NF-κB pathway to generate neutrophil reactive
oxygen species, induce neutrophil apoptosis and increase expression of
proinﬂammatory cytokines. Importantly, the effects of metHb were
synergistic with lipoteichoic acid (LTA), a cell wall component of Staphy-
lococcus aureus that also signals through TLR2. The effects of metHb in
neutrophils were attenuated in the presence of other immune cells indi-
cating modulation of metHb effects in a complex immune environment.
These ﬁndings are important for several reasons. First, the identiﬁca-
tion of TLR2 as a receptor for cell-free Hb is novel, although it must be
noted that the authors did not make direct measurements of metHb-
TLR2 binding so this conclusion is inferred. Second, the observation that
LTA modulates the effects of metHb highlights the need to consider
how interactions of Hb with bacterial products may affect the immune
systemduring sepsis. Third, although the group focusedon the interaction
between metHb and LTA, the fact that metHb alone affects neutrophil
function and survival has broad implications for sepsis in general, not
just sepsis caused by S. aureus. Finally, the demonstration that metHb
acts as a pseudoperoxidase, although not a new ﬁnding, has important
therapeutic implications. In a highly pro-oxidant environment, such as
sepsis, ferrous (2+) Hb can become oxidized to met (3+) and ferrylDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.01.003.
⁎ Corresponding author at: Division of Allergy, Pulmonary, and Critical Care Medicine,
Vanderbilt University School of Medicine, T-1218 MCN, Nashville, TN 37232-2650, USA.
E-mail address: julie.bastarache@vanderbilt.edu (J.A. Bastarache).
http://dx.doi.org/10.1016/j.ebiom.2015.01.019
2352-3964/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND lic(4+)Hb through reactionwithH2O2. Acetaminophen (APAP) is a speciﬁc
hemoprotein reductant that can reduce ferryl Hb to metHb by virtue of
thepseudoperoxidase activity of ferrylHb (Boutaud et al., 2010).Whether
APAP could further reduce metHb to unoxidized ferrous Hb is unknown
but theoretically possible based on the pseudoperoxidase activity of
metHb. Supporting the concept of APAP as a cell-freeHb targeted therapy,
we recently completed a pilot randomized, placebo controlled trial of
APAP in severe sepsis. Subjects treated with APAP had improved renal
function and lower levels of oxidative injury compared to placebo after
3 days of treatment (Janz et al., 2014). The current study by Lee adds fur-
ther biologic rationale for targeting cell-free Hb in patients with severe
sepsis and suggests that such a therapy could have added beneﬁt in sepsis
caused by S. aureus. Finally, these interesting ﬁndings in neutrophils add
to the growing body of literature showing cell-speciﬁc effects of metHb.
MetHb induces proinﬂammatory pathways in both lung epithelial cells
(Mumby et al., 2014) and astrocytes (Gram et al., 2013) but not in vascu-
lar endothelial cells (Silva et al., 2009). These distinct, cell speciﬁc re-
sponses to metHb highlight the need to study the independent effects
of metHb in multiple clinically relevant cell types.
The study by Lee has some limitations that should be commentedon.
First, all of the effects of metHb on neutrophils were studied in vitro;
whether they are biologically relevant in vivo is unknown. Second, the
studies were limited to metHb, so the effects of non-oxidized Hb or
ferryl Hb on neutrophil function are unknown. Along these lines, al-
though there is ample evidence that non-oxidized Hb is elevated in sep-
sis, direct evidence that oxidized (met or ferryl) Hb is elevated in plasma
in patients with sepsis is surprisingly lacking. Detailed analysis of the
extent of oxidation of cell-free Hb in sepsis is needed to guide future
mechanistic studies. Third, the authors show that the effects of metHb
are only partially mediated by TLR2, which begs the question: What
other mechanisms mediate metHb effects? Potential mechanisms
include other cell surface receptors such as TLR4whichmediates the ef-
fects of cell-free Hb in endothelial cells (Lisk et al., 2013) and macro-
phages (Lin et al., 2010) as well as non-receptor mediated effects
through generation of lipid peroxidation products such as isoprostanes
that are known to be associated with poor clinical outcomes in sepsis
(Janz et al., 2014). Future studies will be needed to uncover these alter-
nate mechanisms and test their relevance in vivo.Disclosure
The authors have no relevant conﬂicts of interest to disclose.ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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